Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 3639-3645, November 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, C.-h. B.
Right arrow Articles by Hoffmann, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, C.-h. B.
Right arrow Articles by Hoffmann, D.

Metabolic {alpha}-Hydroxylation of the Tobacco-specific Carcinogen, N'-Nitrosonornicotine1

Chi-hong B. Chen2, Stephen S. Hecht3 and Dietrich Hoffmann

Division of Environmental Carcinogenesis, Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, New York 10595

The metabolism of the tobacco-specific carcinogen, N'-nitrosonornicotine, was studied in the rat. Emphasis was placed on metabolic {alpha}-hydroxylation, which is a likely activation pathway for this compound. Since {alpha}-hydroxynitrosamines are unstable, the hydrolyses of the model compounds 2'-acetoxy-N'-nitrosonomicotine and 5'-acetoxy-N'-nitrosonomicotine were studied to determine the products resulting from decomposition of 2'-hydroxy-N'-nitrosonornicotine and 5'-hydroxy-N'-nitrosonornicotine. Hydrolysis of 2'-acetoxy-N'-nitrosonornicotine gave myosmine (50 to 60%) and 4-hydroxy-1-(3-pyridyl)-1-butanone (5 to 10%) as the main products, whereas 5'-acetoxy-N'-nitrosonornicotine yielded predominantly 2-hydroxy-5-(3-pyridyl)tetrahydrofuran (60 to 70%). Hydrolysis of an additional model compound for 2'-hydroxylation, 4-(N-carbethoxy-N-nitrosamino)-1-(3-pyridyl)-1-butanone also gave 4-hydroxy-1-(3-pyridyl)-1-butanone (50 to 60%). These results support the intermediacy of electrophilic diazohydroxides and/or carbonium ions in the decomposition of 2'-hydroxy-N'-nitrosonornicotine and 5'-hydroxy-N'-nitrosonornicotine. These electrophiles may be active forms of N'-nitrosonornicotine since all three model compounds were mutagenic towards Salmonella typhimurium TA 100 without enzymatic activation.

To demonstrate metabolic {alpha}-hydroxylation of N'-nitrosonornicotine, the products of decomposition of 2'-hydroxy-N'-nitrosonornicotine and 5'-hydroxy-N'-nitrosonornicotine were identified as metabolites. When N'-[2'-14C]nitrosonornicotine was incubated with rat liver microsomes, O2, and a reduced nicotinamide adenine dinucleotide phosphate-generating system, 4-hydroxy-1-(3-pyridyl)-1-butanone and 2-hydroxy-5-(3-pyridyl)tetrahydrofuran were identified as their 2,4-dinitrophenylhydrazone derivatives. Myosmine was also formed in vitro. When male F-344 rats were given s.c. Injections of N'-[2'-14C]nitrosonornicotine, 73 to 85% of the dose appeared in the 48-hr urine. The major metabolites resulting from {alpha}-hydroxylation of N'-nitrosonornicotine in vivo were 4-(3-pyridyl)-4-oxobutyric acid, 4-hydroxy-4-(3-pyridyl)-butyric acid, and 5-(3-pyridyl)tetrahydrofuran-2-one which are metabolic oxidation products of 4-hydroxy-1-(3-pyridyl)-1-butanone and 2-hydroxy-5-(3-pyridyl)tetrahydrofuran.

1 This study was supported by Grant CA-21393 from the National Cancer Institute. This is Paper 11 of the series, "A Study of Chemical Carcinogenesis."

2 To whom requests for reprints should be addressed.

3 Recipient of National Cancer Institute Research Career Development Award 5KO4CA00124.

Received 5/ 5/78. Accepted 7/27/78.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.